High throughput screening and characterization of HIV-1 entry inhibitors targeting gp41: Theories and techniques

Current Pharmaceutical Design

Volumn 10, Issue 15, 2004, Pages 1827-1843

  Liu, Shuwen ^a   Jiang, Shibo ^a  

^a NEW YORK BLOOD CENTER   (United States)

Author keywords

Cell cell fusion; Entry inhibitors; gp120; gp41; High throughout screening; HIV 1; Protein protein interaction; Six helix bundle; Virtual screening; Virus cell fusion

Indexed keywords

ADS J1; ADS J13; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; C PEPTIDE; CD4 ANTIGEN; ENFUVIRTIDE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HYBRID PROTEIN; PROTEIN SUBUNIT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; CARBOXY TERMINAL SEQUENCE; CELL FUSION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG COST; DRUG DETERMINATION; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; HIGH THROUGHPUT SCREENING; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERMINAL REPEAT; MEMBRANE FUSION; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN INTERACTION; REVIEW; TREATMENT FAILURE; VIRUS CELL INTERACTION; VIRUS INFECTIVITY;

ANIMALS; ANTI-HIV AGENTS; DRUG DELIVERY SYSTEMS; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS;

EID: 2442511737     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043384466     Document Type: Review

References (112)

1. D'Souza MP, Cairns JS, Plaeger SF. Current evidence and future directions for targeting HIV entry: therapeutic and prophylactic strategies. JAMA 2000; 284: 215-22.
2. Eckert DM, Kim PS. Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 2001; 70: 777-810.
3. Moore JP, Doms RW. The entry of entry inhibitors: a fusion of science and medicine. Proc Natl Acad Sci USA 2003; 100: 10598-602.
4. Huang L, Zhang L, Chen CH. Potential Drug Targets on the HIV-1 Envelope Glycoproteins, gp120 and gp41. Curr Pharm Des 2003; 9: 1453-62.
5. Jiang S, Zhao Q, Debnath AK. Peptide and Non-peptide HIV Fusion Inhibitors. Curr Pharm Des 2002; 8: 563-80.
6. Meanwell NA, Kadow JF. Inhibitors of the entry of HIV into host cells. Curr Opin Drug Discov Devel 2003; 6: 451-61.
7. Gallo SA, Finnegan CM, Viard M, Raviv Y, Dimitrov A, Rawat SS, et al. The HIV Env-mediated fusion reaction. Biochim Biophys Acta 2003; 1614: 36-50.
8. Kilby JM, Eron JJ. Novel therapies based on mechanisms of HIV-1 cell entry. N Engl J Med 2003; 348: 2228-38.
9. Cooley LA, Lewin SR. HIV-1 cell entry and advances in viral entry inhibitor therapy. J Clin Virol 2003; 26: 121-32.
10. Yang X, Lee J, Mahony EM, Kwong PD, Wyatt R, Sodroski J. Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J Virol 2002; 76: 4634-42.
11. Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997; 89: 263-73.
12. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC. Atomic Structure of the Ectodomain from HIV-1 gp41. Nature 1997; 387: 426-8.
13. Berger EA. HIV entry and tropism: the chemokine receptor connection. AIDS 1997; 11: 3-16.
14. Wyatt R, Sodroski JG. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998; 280: 1884-8.
15. Furuta R, Wild CT, Weng Y, Weiss CD. Capture of an early fusion-active comformation of HIV-1 gp41. Nat Struct Biol 1998; 5: 276-9.
16. Jones P, Korte T, Blumenthal R. Conformational changes in cell surface HIV-1 envelope glycoproteins are triggered by cooperation between cell surface CD4 and coreceptors. J Biol Chem 1998; 273: 404-9.
17. Tan K, Liu J, Wang J, Shen S, Liu M. Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc Natl Acad Sci USA 1997; 94: 12303-8.
18. Wild C, Oas T, McDanal C, Bolognesi D, Matthews T. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci USA 1992; 89: 10537-41.
19. Jiang S, Lin K, Strick N, Neurath AR. HIV-1 inhibition by a peptide. Nature 1993; 365: 113.
20. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA 1994; 91: 9770-4.
21. Wild C, Greenwell T, Shugars D, Rimsky-Clarke L, Matthews T. The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure. AIDS Res Hum Retroviruses 1995; 11: 323-5.
22. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nature Med 1998; 4: 1302-7.
23. Kilby JM, Lalezari JP, Eron JJ, Carlson M, Cohen C, Arduino RC, et al. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses 2002; 18: 685-93.
24. Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in north and south America. N Engl J Med 2003; 348: 2175-85.
25. Bewley CA, Louis JM, Ghirlando R, Clore GM. Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41. J Biol Chem 2002; 277: 14238-45.
26. He Y, Vassell R, Zaitseva M, Nguyen N, Yang Z, Weng Y, et al. Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites. J Virol 2003; 77: 1666-71.
27. Chan DC, Kim PS. HIV entry and its inhibition. Cell 1998; 93: 681-4.
28. Chan DC, Chutkowski CT, Kim PS. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci USA 1998; 95: 15613-7.
29. Kilgore NR, Salzwedel K, Reddick M, Allaway GP, Wild CT. Direct evidence that C-peptide inhibitors of human immunodeficiency virus type 1 entry bind to the gp41 N-helical domain in receptor-activated viral envelope. J Virol 2003; 77: 7669.
30. Root MJ, Kay MS, Kim PS. Protein design of an HIV-1 entry inhibitor. Science 2001; 291: 884-8.
31. Koshiba T, Chan DC. The prefusogenic intermediate of HIV-1 gp41 contains exposed C-peptide regions. J Biol Chem 2003; 278: 7573-9.
32. Louis JM, Bewley CA, Clore GM. Design and properties of N(CCG)-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity. J Biol Chem 2001; 276: 29485-9.
33. Louis JM, Nesheiwat I, Chang L, Clore GM, Bewley CA. Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion. J Biol Chem 2003; 278: 20278-85.
34. Lyne PD. Structure-based virtual screening: an overview. Drug Discov Today 2002; 7: 1047-55.
35. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews 2001; 46: 3-26.
36. Kuntz ID. Structure-based strategies for drug design and discovery. Science 1992; 257: 1078-82.
37. Good AC, Ewing TJ, Gschwend DA, Kuntz ID. New molecular shape descriptors: application in database screening. J Comput Aided Mol Des 1995; 9: 1-12.
38. Selzer PM, Chen X, Chan VJ, Cheng M, Kenyon GL, Kuntz ID, et al. Leishmania major: molecular modeling of cysteine proteases and prediction of new nonpeptide inhibitors. Exp Parasitol 1997; 87: 212-21.
39. Chen Q, Shafer RH, Kuntz ID. Structure-based discovery of ligands targeted to the RNA double helix. Biochemistry 1997; 36: 11402-7.
40. Langer T, Hoffmann RD. Virtual screening: an effective tool for lead structure discovery? Curr Pharm Des 2001; 7: 509-27.
41. Taylor RD, Jewsbury PJ, Essex JW. A review of protein-small molecule docking methods. J Comput Aided Mol Des 2002; 16: 151-66.
42. Waszkowycz B. Structure-based approaches to drug design and virtual screening. Curr Opin Drug Discov Devel 2002; 5: 407-13.
43. Muchmore SW, Hajduk PJ. Crystallography, NMR and virtual screening: integrated tools for drug discovery. Curr Opin Drug Discov Devel 2003; 6: 544-9.
44. Schneider G, Bohm HJ. Virtual screening and fast automated docking methods. Drug Discov Today 2002; 7: 64-70.
45. Ewing TJ, Makino S, Skillman AG, Kuntz ID. DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases. J Comput Aided Mol Des 2001; 15: 411-28.
46. Charifson PS, Corkery JJ, Murcko MA, Walters WP. Consensus scoring: A method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins. J Med Chem 1999; 42: 5100-9.
47. Davis AM, Teague SJ, Kleywegt GJ. Application and limitations of X-ray crystallographic data in structure-based ligand and drug design. Angew Chem Int Ed Engl 2003; 42: 2718-36.
48. Ji H, Shu W, Burling T, Jiang S, Lu M. Inhibition of HIV-1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusion. J Virol 1999; 73: 8578-86.
49. Dwyer JJ, Hasan A, Wilson KL, White JM, Matthews TJ, Delmedico MK. The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation. Biochemistry 2003; 42: 4945-53.
50. Debnath AK, Radigan L, Jiang S. Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodecifiency virus type 1. J Med Chem 1999; 42: 3203-9.
51. Ring CS, Sun E, McKerrow JH, Lee GK, Rosenthal PJ, Kuntz ID, et al. Structure-based inhibitor design by using protein models for the development of antiparasitic agents. Proc Natl Acad Sci USA 1993; 90: 3583-7.
52. Gschwend DA, Sirawaraporn W, Santi DV, Kuntz ID. Specificity in structure-based drug design: identification of a novel, selective inhibitor of Pneumocystis carinii dihydrofolate reductase. Proteins 1997; 29: 59-67.
53. Jiang S, Lin K, Lu M. A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the HIV-1 envelope glycoprotein. J Virol 1998; 72: 10213-7.
54. Jiang S, Lin K, Zhang L, Debnath AK. A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation- specific monoclonal antibody. J Virol Methods 1999; 80: 85-96.
55. Jiang S, Lin K, Neurath AR. Enhancement of human immunodeficiency virus type-1 (HIV-1) infection by antisera to peptides from the envelope glycoproteins gp120/gp41. J Exp Med 1991; 174: 1557-63.
56. Jiang S, Debnath AK. A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity. Biochem Biophys Res Commun 2000; 270: 153-7.
57. Lu M, Blacklow SC, Kim PS. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 1995; 2: 1075-82.
58. Lu M, Kim PS. A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. J Biomol Struct Dyn 1997; 15: 465-71.
59. Liu S, Boyer-Chatenet L, Lu H, Jiang S. Rapid and automated fluorescence-linked immunosorbent assay for high throughput screening of HIV-1 fusion inhibitors targeting gp41. J Biomol Screening 2003; 8: 685-93.
60. Oldenburg KR, Kariv I, Zhang J, Chung TDY, Lin S: Assay miniaturization: Developing technologies and assay formats. In: Seethala R, Fernandes PB (eds.): Handbook of drug screening. New York:Marcel Dekker, Inc., 2001:525-562.
61. Macarron R, Hertzberg RP: Design and implementation of high throughput screening assays. In: Janzen WP (ed): High throughput screening: Method and protocals. New Jersey:Humanan Press Inc., 2002:1-29.
62. Ryu JR, Lee J, Choo S, Yoon SH, Woo ER, Yu YG. Development of an in vitro assay system for screening of gp41 inhibitory compounds. Mol Cells 1998; 8: 717-23.
63. Wild CT, Salzwedel K, Castillo A, Hritz D, Kilgore NR, Allaway GP. [MoPeA3025] A novel high-throughput screening assay for the identification of HIV-1 fusion inhibitors. XIV International AIDS Conference. 2002.
64. Ferrer M, Kapoor TM, Strassmaier T, Weissenhorn W, Skehel JJ, Oprian D, et al. Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements. Nat Struct Biol 1999; 6: 953-60.
65. Feng S, Kapoor TM, Shirai F, Combs AP, Schreiber SL. Molecular basis for the binding of SH3 ligands with non-peptide elements identified by combinatorial synthesis. Chem Biol 1996; 3: 661-70.
66. Zhou G, Ferrer M, Chopra R, Kapoor TM, Strassmaier T, Weissenhorn W, et al. The structure of an HIV-1 specific cell entry inhibitor in complex with the HIV-1 gp41 trimeric core. Bioorg Med Chem 2000; 8: 2219-27.
67. Sodroski J, Goh WC, Rosen C, Campbell K, Haseltine WA. Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity. Nature 1986; 322: 470-4.
68. Tang SB, Levy JA. Parameters involved in the cell fusion induced by HIV. AIDS 1990; 4: 409-15.
69. Zhang G, Chen YH. ELDKWA-epitope-specific monoclonal antibodies inhibit HIV env-mediated syncytium formation. Immunobiology 2003; 207: 259-64.
70. Jiang S, Radigan L, Zhang L. A convenient cell fusion assay for rapid screening for HIV entry inhibitors. Proc SPIE 2000; 3926: 212-9.
71. Jiang S, Lin K, Strick N, Neurath AR. Inhibition of HIV-1 infection by a fusion domain binding peptide from HIV-1 envelope glycoprotein gp41. Biochem Biophys Res Commun 1993; 195: 533-8.
72. Lu H, Zhao Q, Xu Z, Jiang S. Automatic quantitation of HIV-1 mediated cell-to-cell fusion with a digital image analysis system (DIAS): application for rapid screening of HIV-1 fusion inhibitors. J Virol Methods 2003; 107: 155-61.
73. Wunschmann S, Stapleton JT. Fl uorescence-based quantitative methods for detecting human immunodeficiency virus type 1-induced syncytia. J Clin Microbiol 2000; 38: 3055-60.
74. Rocancourt D, Bonnerot C, Jouin H, Emerman M, Nicolas JF. Activation of a beta-galactosidase recombinant provirus: application to titration of human immunodeficiency virus (HIV) and HIV-infected cells. J Virol 1990; 64: 2660-8.
75. Rucker J, Doranz BJ, Edinger AL, Long D, Berson JF, Doms RW. Cell-cell fusion assay to study role of chemokine receptors in human immunodeficiency virus type 1 entry. Methods Enzymol 1997; 288: 118-33.
76. Hong YL, Wu LH, Cui M, McMaster G, Hunt SW, III, Chung FZ. New reporter cell lines to study macrophage-tropic HIV envelope protein-mediated cell-cell fusion. AIDS Res Hum Retroviruses 1999; 15: 1667-72.
77. Genois N, Barbeau B, Olivier M, Tremblay MJ. Inhibition of HIV-1-mediated syncytium formation and virus replication by the lipophosphoglycan from Leishmania donovani is due to an effect on early events in the virus life cycle. Clin Exp Immunol 2001; 124: 32-42.
78. Moir S, Poulin L. Expression of HIV env gene in a human T cell line for a rapid and quantifiable cell fusion assay. AIDS Res Hum Retroviruses 1996; 12: 811-20.
79. Chiba H, Asanuma S, Okamoto M, Inokoshi J, Tanaka H, Fujita K, et al. A simple screening system for anti-HIV drugs: syncytium formation assay using T-cell line tropic and macrophage tropic HIV env expressing cell lines--establishment and validation. J Antibiot (Tokyo) 2001; 54: 818-26.
80. Barbeau B, Fortin JF, Genois N, Tremblay MJ. Modulation of human immunodeficiency virus type 1-induced syncytium formation by the conformational state of LFA-1 determined by a new luciferase-based syncytium quantitative assay. J Virol 1998; 72: 7125-36.
81. Litwin V, Nagashima KA, Ryder AM, Chang CH, Carver JM, Olson WC, et al. Human immunodeficiency virus type 1 membrane fusion mediated by a laboratory-adapted strain and a primary isolate analyzed by resonance energy transfer. J Virol 1996; 70: 6437-41.
82. Huerta L, Lamoyi E, Baez-Saldana A, Larralde C. Human immunodeficiency virus envelope-dependent cell-cell fusion: a quantitative fluorescence cytometric assay. Cytometry 2002; 47: 100-6.
83. Chen YD, Rubin RJ, Szabo A. Fluorescence dequenching kinetics of single cell-cell fusion complexes. Biophys J 1993; 65: 325-33.
84. Potash MJ, Zeira M, Huang ZB, Pearce TE, Eden E, Gendelman HE, et al. Virus-cell membrane fusion does not predict efficient infection of alveolar macrophages by human immunodeficiency virus type 1 (HIV-1). Virology 1992; 188: 864-8.
85. Lapidot M, Loyter A. Fusogenic properties of reconstituted hybrid vesicles containing Sendai and influenza envelope glycoproteins: fluorescence dequenching and fluorescence microscopy studies. Biochim Biophys Acta 1989; 980: 281-90.
86. Sinangil F, Loyter A, Volsky DJ. Quantitative measurement of fusion between human immunodeficiency virus and cultured cells using membrane fluorescence dequenching. FEBS Lett 1988; 239: 88-92.
87. Loyter A, Citovsky V, Blumenthal R. The use of fluorescence dequenching measurements to follow viral membrane fusion events. Methods Biochem Anal 1988; 33: 129-64.
88. Stegmann T, Morselt HW, Scholma J, Wilschut J. Fusion of influenza virus in an intracellular acidic compartment measured by fluorescence dequenching. Biochim Biophys Acta 1987; 904: 165-70.
89. Eckert DM, Kim PS. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proc Natl Acad Sci USA 2001; 98: 11187-92.
90. Winzor DJ, Harding SE. Sedimentation equilibrium in the analytical ultracentrifuge. In Harding SE, Chowdhry BZ (ed): Protein-ligand interaction: hydrodynamics and calorimetry, New York, Oxford University Press, 2001; 105-35.
91. An BS, Ryu JR, Ahn K, Yu YG. Design of a peptide inhibitor that blocks the cell fusion mediated by glycoprotein 41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2000; 16: 1797-804.
92. Zhao Q, Ernst JT, Hamilton AD, Debnath AK, Jiang S. XTT formazan widely used to detect cell viability inhibits HIV type 1 infection in vitro by targeting gp41. AIDS Res Hum Retroviruses 2002; 18: 989-97.
93. Ernst JT, Kutzki O, Debnath AK, Jiang S, Lu H, Hamilton AD. Design of a protein surface antagonist based on alpha-helix mimicry: inhibition of gp41 assembly and viral fusion. Angew Chem Int Ed Engl 2002; 41: 278-81.
94. Liu S, Zhao Q, Jiang S. Determination of the HIV-1 gp41 postfusion conformation modeled by synthetic peptides: applicable for identification of the HIV-1 fusion inhibitors. Peptide 2003; 24: 1303-13.
95. Blair WS, Lin PF, Meanwell NA, Wallace OB. HIV-1 entry - an expanding portal for drug discovery. Drug Discov Today 2000; 5: 183-94.
96. Zwick MB, Saphire EO, Burton DR. gp41: HIV's Shy protein. Nat Med 2004; 10: 133-4.
97. De Clercq E. New developments in anti-HIV chemotherapy. Curr Med Chem 2001; 8: 1529-58.
98. LaBranche CC, Galasso G, Moore JP, Bolognesi DP, Hirsch MS, Hammer SM. HIV fusion and its inhibition. Antiviral Res 2001; 50: 95-115.
99. De Clercq E. New anti-HIV agents and targets. Med Res Rev 2002; 22: 531-65.
100. Cochran AG. Protein-protein interfaces: mimics and inhibitors. Curr Opin Chem Biol 2001; 5: 654-9.
101. Ockey DA, Gadek TR. Inhibitors of protein-protein interactions. Expert Opin Ther Pat 2002; 12: 393-400.
102. Toogood PL. Inhibition of protein-protein association by small molecules: approaches and progress. J Med Chem 2002; 45: 1543-58.
103. Lo CL, Chothia C, Janin J. The atomic structure of protein-protein recognition sites. J Mol Biol 1999; 285: 2177-98.
104. Gadek TR, Nicholas JB. Small molecule antagonists of proteins. Biochem Pharmacol 2003; 65: 1-8.
105. Jones S, Thornton JM. Principles of protein-protein interactions. Proc Natl Acad Sci USA 1996; 93: 13-20.
106. Bogan AA, Thorn KS. Anatomy of hot spots in protein interfaces. J Mol Biol 1998; 280: 1-9.
107. Berg T. Modulation of protein-protein interactions with small organic molecules. Angew Chem Int Ed Engl 2003; 42: 2462-81.
108. Lin PF, Blair W, Wang T, Spicer T, Guo Q, Zhou N, et at. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc Natl Acad Sci USA 2003; 100: 11013-8.
109. Shu W, Liu J, Ji H, Radigan L, Jiang S, Lu M. Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides. Biochemistry 2000; 39: 1634-42.
110. Huang L, Zhang L, Chen CH. Potential drug targets on the HIV-1 envelope glycoproteins, gp120 and gp41. Curr Pharm Design 2003; 9(18): 1453-62.
111. Jiang S, Zhao, Q, Debnath AK. Peptide and non-peptide HIV fusion inhibitors. Curr Pharm Design 2002; 8(8): 563-80.
112. Morris-Natschke SL, Ishaq KS, Kucera LS. Phospholipid analogs against HIV-1 infection and disease. Curr Pharm Design 2003; 9(18): 1441-51.